Published in Lab Business Week, June 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Cytos Biotechnology.
Report 1: Cytos Biotechnology AG (SWX:CYTN) announced today that it has entered into an exclusive global commercial license agreement with Novartis (NYSE:NVS) to develop, manufacture and commercialize CYT002-NicQb, a therapeutic vaccine in phase II clinical development for the treatment of nicotine addiction.
Under the terms of the agreement, Novartis is granted world-wide exclusive rights for CYT002-NicQb and is responsible for late stage...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.